长春高新：子公司注射用GenSci143境外生产药品注册临床试验申请获得批准

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has received approval for the clinical trial application of GenSci143 in the United States, which is a bispecific antibody-drug conjugate developed for the treatment of advanced solid tumors such as prostate cancer and lung cancer [1] Group 1 - GenSci143 is independently developed by Jinsai Pharmaceutical [1] - The drug has already been approved for clinical trials in China for advanced solid tumors [1]